Agilent wins FDA approval for PD-L1 IHC 28-8 test in gastric and esophageal cancers

• Agilent won FDA clearance for its PD-L1 IHC 28-8 pharmDx test in certain gastric and esophageal cancers.
• The label supports use as a companion diagnostic to identify patients for Bristol Myers Squibb’s Opdivo or Opdivo Qvantig.
• The assay is authorized for detecting PD-L1 expression at CPS ≥ 1, run exclusively on Agilent’s Autostainer Link 48 system.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607140800BIZWIRE_USPR_____20260714_BW470296) on July 14, 2026, and is solely responsible for the information contained therein.